Clinical trial NCT06922656: Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?
Official title: Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE4
Conditions: Type 1 Diabetes (T1D)
Keywords: Ketoacidosis, Hypoglycemia, Glucose Control, SGLT2 Inhibitors, TZD, Pioglitazone, T1D
Lead sponsor: Dasman Diabetes Institute
Sponsor class: OTHER
First posted: 2025-04-10
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Eligible subjects without evidence of hypoglycemia will be randomized in a double blind fashin into two groups to receive for 16 weeks in a double-blind fashion the following: Group 1 will be started on dapagliflozin 10 mg per day plus 30 mg pioglitazone. If well tolerated, the pioglitazone dose will be increased to 45 mg after 2 weeks. Subjects in Group 2 will receive matching placebo.

Subjects in both groups will be provided with ketone meters and will be asked to measure their plasma ketone concentration every morning. If the plasma ketone concentration exceeds 1.0 mM, subjects will be instructed to contact the study nurse coordinator.
Primary purpose: TREATMENT

Brief summary: Previous data from our clinical trial has demonstrated that the combination of dapagliflozin plus pioglitazone cause robust decrease in the plasma glucose concentration without significant increase in plasma ketone concentration in subjects with T1DM receiving multiple insulin injections or insulin pump. Although patients receiving insulin therapy with pump have participated in the study, none has insulin delivered in automated pump (780 pump) which automatically adjusts the rate of insulin infusion based upon the measured plasma glucose concentration. Although automated insulin pumps have been introduced to practice only last year, they are gaining popularity in the care of T1DM patients worldwide. The aim of this amendment is to demonstrate the efficacy (decrease in HbA1c) and safety (no significant increase in plasma ketone concentration) of combination of dapagliflozin plus pioglitazone in T1DM patients receiving insulin therapy with automated insulin pump.

Detailed description: Insulin Pumps Participants The interim analysis of our previous study has demonstrated that the combination of dapagliflozin plus pioglitazone cause robust decrease in the plasma glucose concentration without significant increase in plasma ketone concentration in subjects with T1DM receiving multiple insulin injections or insulin pump. Although patients receiving insulin therapy with pump have participated in the study, none has insulin delivered in automated pump (780 pump) which automatically adjusts the rate of insulin infusion based upon the measured plasma glucose concentration. Although automated insulin pumps have been introduced to practice only last year, they are gaining popularity in the care of T1DM patients worldwide. The aim of this amendment is to demonstrate the efficacy (decrease in HbA1c) and safety (no significant increase in plasma ketone concentration) of combination of dapagliflozin plus pioglitazone in T1DM patients receiving insulin therapy with automated insulin pump.

1. The primary objective of the study is to examine the decrease in HbA1c caused by pioglitazone plus dapagliflozin versus placebo in T1DM patients receiving automated insulin delivery (780 pump).
2. Secondary objectives of the study are to examine the effect of pioglitazone plus dapagliflozin on plasma ketone concentration, time in range, body weight and rate of hypoglycemia.

Research Design:

Inclusion Criteria:

1. Age \>18 years
2. T1DM
3. Other than diabetes, subjects must be in good general health as determined by physical exam, medical history, Chem 20, CBC, TSH, urinalysis, and EKG.
4. Fasting C-peptide concentration \<0.7 ng/ml
5. Poor glycemic control (HbA1c=7.0-11.0%)
6. Treatment with multiple daily insulin injections (basal plus prandial) or insulin pump
7. Total daily insulin dose ≥0.6 U/kg per day
8. Stable insulin dose (±4 units) in the preceding three months.
9. eGFR≥60 ml/min.
10. Weight stable over the preceding 3 months (± 3 pounds) and who do not participate in an excessively heavy exercise program

Exclusion Criteria

1. T2DM
2. Daily insulin dose \<0.6 U/kg per day
3. Fasting C-peptide \>0.7 ng/ml
4. HbA1c \<7.0% or \>11.0%
5. eGFR\<60 ml/min
6. Hematuria in urine analysis
7. Pregnancy, lactating, positive pregnancy test or planning to become pregnant in the following year. Women of child-bearing potential will be requested to use at least two barrier methods before being enrolled in the study.
8. Major organ system disease which includes: (i) malignancy or history of malignancy including bladder cancer; (ii) Congestive heart failure or history of coronary heart disease or any other cardiac disease; (iii) chronic liver disease or LFT \>3 times the upper normal level; (iv) History of alcohol or drug abuse; (v) History of chronic lung disease (e.g., COPD, asthma); (vi) history of rheumatic disease; (vii) History of chronic pancreatitis or pancreatic surgery; (viii) History of CVA or TIA (ix) Planned surgery during the study; (x) history of HIV infection or other immune compromised disease; and history of organ transplantation; (xi) patients who take medications, other than insulin, known to affect glucose metabolism, e.g., prednisone.
9. Evidence of proliferative diabetic retinopathy
10. Patients enrolled in a heavy exercise program
11. Patients on ketogenic diet
12. History of hospitalization for DKA, hypoglycemia or uncontrolled hyperglycemia in the preceding 6 month.
13. Presence of symptoms of poor glycemic control, e.g. polydipsia or polyurea
14. History of hypersensitivity to dapagliflozin or pioglitazone

Patients will be screened as follows:

1. Screening: Patients will be screened with medical history and physical examination. Blood will be drawn for CBC, Chem 20, lipid profile, TSH, fasting insulin, C-Peptide, ketones, pregnancy test and urine analysis. All measurements will be performed in the morning after 10-12 hours overnight fast.
2. Run in Period (week 1-4) Following determination of eligibility, subjects will receive Fasting Measurement of: plasma glucose, insulin, C-peptide, glucagon, GLP-1, GIP, HbA1c, FFA, ketones, lactate, ProBNP, CBC, blood chemistries, lipid profile, erythropoietin, creatinine, uric acid, Na, K, Cl, HCO3, PH, Ca, urinary creatinine to microalbumin ratio and urinary creatinine to glucose ratio. EGFR will be calculated using the National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) calculator CKD-EPI using Creatinine Equation while adjusting for body surface to estimate GFR. This is centralized for all centers and done by the team in Texas diabetes Institute. A copy of the eGFR calculation and results will be included in the patients file. After completing the fasting measurements, subjects will start a 4 week run in period during which they will be instructed to continue their daily insulin regimen unchanged unless instructed otherwise by the study team. They also will be instructed to continue their measurement of daily glucose levels at least 4 times each day (before each meal and at bed time) to determine the baseline rate of hypoglycemia. Subjects will be instructed to continue with this schedule of home measurement of plasma glucose levels until the end of the study (week 32), and to bring the results of the measurement at each follow-up visit.

During the run in period, patient compliance will be evaluated by examining their diary of insulin dose injection, and blood sugar levels. The daily insulin dose in the diary will be contrasted with the measured fasting plasma insulin concentration. It should be noted that, the vast majority of patients will be recruited by the investigators from T1DM patients who are under their care for long period of time and their compliance with T1DM treatment is well known to investigators (see page 18 below).

Home-measured blood glucose values will be reviewed at the end of week one of the run in period, subjects with evidence for hypoglycemia or who have FPG \<120 mg/dl (measured with glucometer after overnight fast) will have their daily insulin dose adjusted according to the algorithm below (Basal insulin adjustment) to achieve a goal of a mean FPG \>120 mg/dl as measured with glucometer in home-measured plasma glucose levels during week 4. Since the primary aim of the present study is to examine the efficacy of SGLT2 inhibitor with and without pioglitazone on the HbA1c, no adjustment in insulin dose will be done during the run in period or at the time of starting dapagliflozin in patients without evidence of hypoglycemia and FPG \>120 mg/dl, in order not to affect the decrease in HbA1c caused by SGLT2 inhibitor and not to increase the risk of ketoacidosis. Changes in daily insulin dose will be allowed after starting dapagliflzoin therapy to avoid hypoglycemia (see algorithm below) and will be made based upon the home-measured plasma glucose levels and the CGM results, and the discretion of the investigator. Since previous studies (41) have demonstrated that \<20% decrease in daily insulin dose minimizes the risk of ketoacidosis. The change in insulin dose at each follow-up visit will be limited to \<10% of the daily dose. Plasma ketone concentration will be measured on the following day before making additional insulin dose adjustment if necessary. This plan of insulin dose adjustment minimizes the reduction in insulin dose to the minimum required to avoid hypoglycemia and minimizes the risk of ketoacidosis. Subjects with evidence of hypoglycemia will not be allowed to start dapagliflozin therapy before CGM confirms the elimination of hypoglycemic episodes.

Patients whose daily insulin dose required adjustment (because of hypoglycemia) will be seen weekly during the run in period, and the daily insulin dose will be adjusted to ensure a FPG concentration \>120 mg/dl at 4 weeks without hypoglycemic events.

Eligible subjects will enter the run in period in which the pump parameters will be adjusted in patients experiencing hypoglycemic events in order to be eliminated.

During the run in period subjects will be asked to fill a questionnaire aims at examining the satisfaction from glucose management and the impact of combination therapy with pioglitazone plus dapagliflozin on the quality of glucose management (see questionnaire below). Subjects will be asked to fill the quality of life questionnaire at the las clinic follow-up visit.

Eligible subjects without evidence of hypoglycemia will be randomized into two groups to receive for 16 weeks in a double-blind fashion the following: Group 1 will be started on dapagliflozin 10 mg per day plus 30 mg pioglitazone. If well tolerated, the pioglitazone dose will be increased to 45 mg after 2 weeks. Subjects in Group 2 will receive matching placebo.

Subjects in both groups will be provided with ketone meters and will be asked to measure their plasma ketone concentration every morning. If the plasma ketone concentration exceeds 1.0 mM, subjects will be instructed to contact the study nurse coordinator.

Follow-up visits After starting therapy, subjects will be seen in the clinic (Clinic visit) every 4 weeks. Telephone calls (phone visits) also will be done by the study nurse every 2 weeks or as needed. During each follow-up visit (phone or clinic), brief medical history will be performed. Patients will be questioned about their medical history and their general health since last follow-up visit. They will be asked open ended questions e.g. "Have you had any health problems since the last visit". CGM data and ketone levels will be reviewed and recorded by the study nurse coordinator. If hypoglycemic events occur, changes to the pump parameters (e.g. carbs ratio, glucose target, and active insulin time) will be made to eliminate hypoglycemic events. Otherwise, no adjustment in pump parameters will be done during the study.

During the clinic visit, physical examination will be made, and body weight, blood pressure and pulse will be measured. Blood sample will be drawn for the measurement of FPG, ketone, glucagon, and FFA concentrations, and HbA1c. Subjects will be instructed to maintain telephone contact with the study nurse coordinator and inform him/her about any event of hypoglycemia, sudden increase in plasma glucose concentration, or an increase in plasma ketone concentration \> 1.0 mM, or other health related issues should they occur.

Hypoglycemia will be defined as blood sugar levels \<70 mg/dl, or hypoglycemic symptoms that subside after carbohydrate ingestion and will be measured as time below range. Severe hypoglycemia will be defined as hypoglycemia requiring third party assistance.

subjects will be provided with pens of degludec as a back up for use in case of technical issue with the pump and will be advised to immediately inject an insulin dose equal to their basal insulin regimen in case of technical problem with the pump and contact one of the study team immediately to test the pump function.

Management of Plasma Ketone Concentrations We will instruct patients at the time of starting therapy (dapagliflozin plus pioglitazone or placebo) to increase fluid consumption by 1 liter per day to compensate for urinary water loss (mean of 400 ml) caused by dapagliflozin. Patients also will be instructed about the signs and symptoms of diabetic keto acidosis (nausea, abdominal pain, rapid breathing etc.).

If at any time, plasma ketone concentration exceeds 1.0 mM, patients will be instructed to immediately contact the study nurse coordinator. Possible precipitating factor for ketosis will be examined (e.g., acute illness or stress). Insulin pump will be tested to rule out pump failure. Patients will be questioned about their diet and insulin injections to ensure that the increase in plasma ketone concentration is not due to non-adherence to therapy or due to pump or technical failure.

If precipitating factor for ketosis is identified. Subjects will be asked to hold therapy until it is resolved, after which time it will be restarted.

If a precipitating factor is ruled out and the increase in plasma ketone concentration \>1.0 mM persists for 3 consecutive days, or the plasma ketone concentration continue to raise and exceed 1.5 mM, it will be considered drug induced ketosis. Subjects will be unblinded. If the ketosis occurred in subject receiving dapagliflozin plus pioglitazone, the study will be terminated. The insulin dose is escalated until the ketosis is resolved. However, if patient is receiving placebo, open label dapagliflozin plus pioglitazone (45 mg) will be started and continued for 16 weeks. Patients will continue with the regular visit schedule until the end of study.

If an increase in plasma ketone concentration occurs in subjects receiving open label dapagliflozin plus pioglitazone, the drug therapy will be discontinued, the insulin dose is escalated and the study is terminated.

Primary outcome of the Study: is the change from baseline to week 16 in the HbA1c.

Secondary outcomes include:

1. Change from baseline to week 16 in plasma ketone concentration
2. Change from baseline to week 16 in time in range, and time above range
3. Incidence of hypoglycemia measured as time below range
4. Change from baseline to week 16 in body weight Sample Size Calculation We have powered the study to detect a 0.5 mM reduction in the HbA1c (which is clinically meaningful) from week 0 to week 16. In previous studies, the standard deviation of the change in HbA1c was 0.6%. We computed that 22 participants provide 90% power to detect 0.5% reduction in the treatment arm compared to placebo at alpha \< 0.05. to ensure 22 completers in each arm, we have set the sample size to 30 in each group.

DATA ANALYSIS

The with-subject change in HbA1c from week 0 to week 16 in pioglitazone plus dapagliflozin-treated subjects will be compared to subjects receiving placebo with two way ANVOA. This contrast will represent the effect of dapagliflozin plus pioglitazone on HbA1c in T1DM patients relative to placebo. Mixed effects linear models will be used to contrast treatment groups with regard to all 5 repeated HbA1c measures between week 0 and week 16 in terms of time and treatment (placebo, pioglitazone plus dapagliflozin) and the treatment by time interaction. Results will be described with whiskered line plots by treatment group. The effect of pioglitazone plus dapagliflozin relative to placebo on time in range, plasma ketone, glucagon, and FFA concentrations, and body weight will be addressed similarly.

The significance in the difference in the occurrence of adverse events with treatment (Placebo, Pioglitazone plus dapagliflozin) will be assessed with Fisher's exact tests in the safety population of patients who receive at least one dose of placebo or pioglitazone plus dapagliflozin. All efficacy analyses will be carried out in randomized patients who receive at least one dose of placebo or pioglitazone plus dapagliflozin (the same as the safety population). All adverse events will be tabulated by treatment group, preferred term, seriousness (serious, not serious), severity (severe, not severe), and relatedness to treatment (not related, possibly related, probably related, related). All chemistries will be summarized by treatment group, and visit, and changes from baseline. The mean, standard deviation, median, minimum and maximum of continuously distributed outcomes will be reported. Frequencies and percentages of categorical and binary outcomes will be tabulated. A consort diagram describing the number screened, the number of screen failures by reason, the number randomized by treatment group, and by treatment the number lost follow-up with reason by reason, and the number completing the study per protocol. Efficacy will be assessed in the per protocol population of patients who complete the study per protocol. The results of the intent-to-treat assessments of efficacy will be considered of primary importance.

Anticipated results

We anticipate a significant decrease in the HbA1c in subjects receiving dapagliflozin plus pioglitazone compared to placebo, and the decrease in HbA1c will be associated with significant increase in TIR and decrease in the time above range without an increase in time below range, demonstrating the safe reduction in the HbA1c by dapagliflozin plus pioglitazone without increased risk of hypoglycemia.

We anticipate that the decrease in HbA1c in subjects receiving dapagliflozin plus pioglitazone will be associated with a significant decrease in the daily insulin dose required. Importantly, despite the decrease in daily insulin dose, subjects receiving dapagliflozin plus pioglitazone will not experience any significant increase in plasma FFA or ketone concentrations, further, emphasizing the safety of decrease in HbA1c caused by the combination of dapagliflozin plus pioglitazone in T1DM patients receiving automated insulin delivery. Therefore, the results of the present study will establish the combination of pioglitazone plus dapagliflozin as an effective and safe adjunct therapy to insulin in T1DM patients receiving automatic insulin delivery.

Eligibility criteria: Inclusion Criteria:

- 1) Age \>18 years 2) T1DM 3) Other than diabetes, subjects must be in good general health as determined by physical exam, medical history, Chem 20, CBC, TSH, urinalysis, and EKG.

4) Fasting C-peptide concentration \<0.7 ng/ml 5) Poor glycemic control (HbA1c=7.0-11.0%) 6) Treatment with multiple daily insulin injections (basal plus prandial) or insulin pump 7) Total daily insulin dose ≥0.6 U/kg per day 8) Stable insulin dose (±4 units) in the preceding three months. 9) eGFR≥60 ml/min. 10) Weight stable over the preceding 3 months (± 3 pounds) and who do not participate in an excessively heavy exercise program

Exclusion Criteria:

* 1) Age \>18 years 2) T1DM 3) Other than diabetes, subjects must be in good general health as determined by physical exam, medical history, Chem 20, CBC, TSH, urinalysis, and EKG.

  4) Fasting C-peptide concentration \<0.7 ng/ml 5) Poor glycemic control (HbA1c=7.0-11.0%) 6) Treatment with multiple daily insulin injections (basal plus prandial) or insulin pump 7) Total daily insulin dose ≥0.6 U/kg per day 8) Stable insulin dose (±4 units) in the preceding three months. 9) eGFR≥60 ml/min. 10) Weight stable over the preceding 3 months (± 3 pounds) and who do not participate in an excessively heavy exercise program

Primary outcomes:
measure: HbA1C Reduction
timeFrame: 16 weeks
Secondary outcomes:
measure: Time in Range
timeFrame: 16 weeks
Other outcomes:
Locations:
city: Kuwait City
country: Kuwait
facility: Dasman Diabetes Institute
city: Qatar
country: Qatar
facility: Hamad Medical Corporation
state: Doha
city: Riyadh
country: Saudi Arabia
facility: Diabetes and Endocrine Treatment Center, Prince Sultan Military Medical City. Kidney & Pancreas Health Centre, Organ Transplant Centre of Excellence, King Faisal Specialist Hospital & Research Centre, Alfaisal Univeristy, Riyadh, Kingdom of Saudi Arabia
Study officials:
affiliation: Dasman Diabetes Institute
name: Fahd Al-Mulla, MD, PhD
role: STUDY_CHAIR
affiliation: Texas Diabetes Institute, Dasman Diabetes Institute
name: Muhammed Abdul Ghani, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Dasman Diabetes Institute
name: Mohamed Abu-Farha, PhD
role: STUDY_DIRECTOR
References: